Open AccessThe effect of site‐specific monoclonal antibodies directed to toxic shock syndrome toxin‐1 in experimental Staphylococcus aureus arthritis
Author(s) -
Margareta Verdrengh,
Winnie W. S. Kum,
Anthony W. Chow,
Andrzej Tarkowski
Publication year - 1999
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1046/j.1365-2249.1999.01061.x
Subject(s) - staphylococcus aureus , toxic shock syndrome , monoclonal antibody , immunology , arthritis , toxin , microbiology and biotechnology , medicine , staphylococcal infections , shock (circulatory) , antibody , biology , bacteria , genetics
Staphylococcus aureus produces a large number of potential virulence factors, among these the superantigen toxic shock syndrome toxin‐1 (TSST‐1). We have recently demonstrated that TSST‐1 is involved in the pathogenesis of septic arthritis. Recent data show that the TSST‐1 molecule is composed of two distinct domains, one proposed to interact with T cell receptor (TCR) and one with the MHC class II. The aim of this study was to assess if interaction between TSST‐1‐specific MoAbs directed to sites on the MHC and/or TCR Vβ affects the development of experimental S. aureus ‐induced arthritis. For that purpose we used a panel of seven MoAbs, which were injected intraperitoneally before and after inoculation with a TSST‐1‐producing S. aureus strain. Administration of antibodies did not affect the development of arthritis, suggesting inefficacy of such a procedure in neutralization of exotoxin‐mediated disease manifestations.